SAN FRANCISCO, Aug. 24 /PRNewswire/ -- Gentiae Clinical Research, Inc. a provider of centralized cardiac safety monitoring & imaging services, announced today record revenue growth for the first three quarters of fiscal year 2005. In anticipation of the company's ongoing rapid growth, Gentiae announced the appointment of Craig Albright as its new chief executive officer.
"On behalf of Gentiae's board of directors, I'm very excited to welcome Craig to our team," said board member Mike Kaplan, of venture firm Three Arch Partners. "With his track record in health care, and his credibility in the financing community, Craig will provide Gentiae with the leadership it needs to expand on its current success." Added board member Bill Hinton, "We're at a pivotal time in the company's expansion, and Craig has the experience to build and lead the team at Gentiae to take advantage of an exceptional market opportunity."
"I'm delighted to join Gentiae as it transitions for the next stage of growth," said Albright, "and it is a privilege to build on the success of the company to date. FDA scrutiny and concern for cardiac safety is creating a tremendous market opportunity for ECG and other cardiovascular core lab services. The company's founding management team has built Gentiae into a true clinical brand that is recognized in the industry as the quality standard."
As CEO of Free & Clear, Inc., recipient of multiple industry awards for clinical excellence, Albright led the company through its spinout from parent Group Health Cooperative and through subsequent rounds of venture financing to become a commercial leader in the disease management and risk factor treatment market. Over the past 20 years, Albright has helped lead the rapid growth of several notable venture backed health care companies, including Vivra Specialty Partners, Inc. and Datis Corporation. Albright has also served as a retained advisor to several leading private equity groups, including Three Arch, Kohlberg & Company, and Warburg Pincus.
Gentiae spun off from its parent organization, the Ischemia Research and Education Foundation (IREF), in September of 2001. It has received funding from IREF and Three Arch Partners of Portola Valley, California.
In addition to appointing a new CEO, Gentiae has also announced that Jay B. Hunt has joined the Gentiae Board of Directors.
Gentiae Clinical Research, Inc., based in the San Francisco Bay Area, is an internationally recognized provider of cardiovascular core laboratory services including electrocardiography (ECG), Holter, echocardiography (ECHO), angiography, and MUGA. As a spin-off from the Ischemia Research and Education Foundation, Gentiae's ECG central laboratory inherits more than 18 years of experience interpreting cardiac safety data for global studies. Gentiae conducts research worldwide and provides a range of clinical trial management services that include protocol design, trial management, project management, data management, site monitoring, biostatistical analysis, report writing, and regulatory support. Gentiae manages the collection, measurement, clinical interpretation, analysis, archiving and submission of digital ECG data and diagnostic images through its LifeSignals(TM) technology platform.
The name Gentiae, based on a Latin root, means "people of the world." More information about Gentiae can be found at www.gentiae.com.
Gentiae Clinical Research, Inc.